Cancer and Tumor Profiling Market Size, Share, Growth, and Industry Analysis, By Type (Genomics, Proteomics, Metabolomics, Epigenetics), By Application (Personalized Cancer Medicine, Oncological Diagnostics, Research), Regional Insights and Forecast to 2035

Cancer and Tumor Profiling Market Overview

The Cancer and Tumor Profiling Market is witnessing significant expansion due to increasing global cancer incidence, rising adoption of precision oncology, and growing integration of genomic technologies in clinical diagnostics. More than 20 million new cancer cases were reported globally in 2024, while over 10 million cancer-related deaths accelerated the demand for advanced tumor profiling solutions. Cancer and Tumor Profiling Market Analysis indicates that next-generation sequencing technologies account for nearly 48% of molecular diagnostic testing procedures used in oncology laboratories. 

The USA remains the largest contributor to the Cancer and Tumor Profiling Market Share due to high oncology testing volumes, advanced healthcare infrastructure, and rapid precision medicine adoption. More than 2 million new cancer cases were diagnosed in the United States during 2024, with lung, breast, colorectal, and prostate cancers accounting for over 52% of total diagnoses. Approximately 72% of major cancer hospitals in the country utilize genomic profiling technologies for treatment planning. Liquid biopsy testing procedures increased by 41% across U.S. oncology laboratories, while demand for personalized cancer therapy expanded by 46%. 

Download Free Sample to learn more about this report.

Key Findings

• Market Size & Growth: Over 20 million global cancer cases generated strong demand for tumor profiling technologies, while biomarker-based oncology testing utilization increased by 39% across diagnostic laboratories.
• Key Market Driver: Precision oncology adoption increased by 46%, genomic sequencing procedures rose by 44%, biomarker testing demand expanded by 39%, and personalized therapy utilization exceeded 51% across oncology treatment centers globally.
• Major Market Restraint: More than 37% of healthcare facilities reported high genomic testing costs, while 32% of smaller laboratories experienced reimbursement limitations and 29% faced shortages of trained molecular pathology professionals.
• Emerging Trends: Liquid biopsy adoption increased by 41%, AI-driven genomic analysis implementation rose by 36%, multi-omics integration expanded by 33%, and cloud-based oncology data platforms recorded 31% higher utilization.
• Regional Leadership: North America accounted for nearly 42% of advanced oncology genomic testing procedures, while Asia-Pacific recorded 38% growth in cancer biomarker screening programs across emerging healthcare systems.
• Competitive Landscape: More than 58% of leading oncology diagnostic companies focused on strategic partnerships, while 43% invested in AI-enabled sequencing platforms and 35% expanded companion diagnostic portfolios.
• Market Segmentation: Genomic profiling represented approximately 48% of testing demand, liquid biopsy contributed 27%, proteomic profiling accounted for 15%, and hospital laboratories generated nearly 54% of end-user adoption.
• Recent Development: Around 45% of oncology diagnostic firms launched advanced NGS panels, 34% expanded biomarker databases, and 29% introduced automated genomic interpretation software for clinical applications.

Cancer and Tumor Profiling Market Latest Trends

The Cancer and Tumor Profiling Market Trends are strongly influenced by rapid developments in next-generation sequencing, liquid biopsy technologies, and AI-powered genomic analytics. More than 48% of oncology diagnostic laboratories globally now use NGS-based tumor profiling systems for identifying actionable mutations and selecting targeted therapies. Liquid biopsy testing adoption increased by 41% because of its minimally invasive nature and faster turnaround times. More than 60% of pharmaceutical companies developing oncology drugs currently integrate biomarker profiling into clinical trial protocols. 

Another important trend shaping the Cancer and Tumor Profiling Market Forecast is the expansion of personalized medicine programs and companion diagnostics. More than 55% of oncologists globally now prefer molecular profiling before initiating targeted therapy treatments. Multi-omics technologies combining genomics, transcriptomics, and proteomics increased by 33% in precision oncology research projects. Asia-Pacific countries recorded a 38% increase in cancer genomic screening initiatives supported by public healthcare investments. Additionally, cloud-based oncology data management platforms witnessed 31% higher deployment among hospitals handling large genomic datasets. 

Cancer and Tumor Profiling Market Dynamics

DRIVER

"Rising adoption of precision oncology and genomic diagnostics"

The growing adoption of precision medicine remains the primary growth driver for the Cancer and Tumor Profiling Market. More than 52% of oncology treatment centers worldwide now integrate genomic profiling into routine cancer care. Approximately 48% of oncologists utilize biomarker-driven therapy selection for lung, breast, and colorectal cancers. Advances in sequencing technologies reduced genomic testing turnaround time by nearly 37%, increasing physician preference for molecular diagnostics. More than 1,900 active oncology clinical trials currently involve genomic biomarkers, while targeted cancer therapies represented over 45% of newly approved oncology drugs. 

RESTRAINTS

"High costs associated with advanced tumor profiling technologies"

Despite strong adoption trends, high operational and testing costs remain major restraints for the Cancer and Tumor Profiling Market. Approximately 37% of healthcare facilities report financial limitations in implementing advanced genomic sequencing systems. Molecular diagnostic instruments require substantial infrastructure investments, while nearly 32% of regional laboratories experience reimbursement challenges for biomarker testing procedures. Data interpretation complexity also increases operational expenditures, as around 29% of oncology centers report shortages of trained bioinformatics professionals. 

OPPORTUNITY

"Expansion of liquid biopsy and AI-integrated oncology platforms"

The increasing commercialization of liquid biopsy technologies presents substantial opportunities in the Cancer and Tumor Profiling Market. Liquid biopsy adoption increased by 41% globally due to its ability to detect tumor DNA through minimally invasive procedures. More than 36% of oncology research centers now use AI-enabled genomic interpretation tools to accelerate biomarker analysis and treatment recommendations. Multi-cancer early detection programs expanded by 30% across developed healthcare systems, creating demand for advanced profiling technologies. Pharmaceutical collaborations with diagnostic companies increased by 40% to develop companion diagnostics for targeted therapies. 

CHALLENGE

"Data complexity and regulatory standardization issues"

Managing large-scale genomic datasets and maintaining regulatory compliance remain major challenges in the Cancer and Tumor Profiling Market. More than 44% of oncology laboratories report difficulties in handling complex genomic sequencing data generated during tumor analysis. Variability in biomarker testing standards across countries affects nearly 31% of cross-border oncology research collaborations. Data privacy regulations and patient genomic security requirements increased compliance costs by 27% for diagnostic providers.

Cancer and Tumor Profiling Market Segmentation

The Cancer and Tumor Profiling Market Segmentation is categorized by type and application, reflecting the growing adoption of advanced molecular diagnostics and precision oncology technologies. By type, genomics accounts for nearly 48% of total testing procedures due to increasing next-generation sequencing adoption, while proteomics contributes approximately 24% because of rising biomarker discovery activities. Metabolomics represents around 16% owing to expanding cancer metabolism research, and epigenetics holds nearly 12% supported by increasing DNA methylation studies. 

Download Free Sample to learn more about this report.

BY TYPE

Genomics: Genomics represents the largest segment within the Cancer and Tumor Profiling Market due to the extensive use of genomic sequencing technologies in precision oncology and targeted cancer treatment planning. More than 48% of molecular diagnostic procedures in oncology involve genomic profiling platforms, particularly next-generation sequencing technologies. Approximately 72% of leading cancer hospitals globally use genomic testing to identify mutations in lung, colorectal, breast, and prostate cancers. The demand for genomic biomarker analysis increased by 44% because of growing adoption of companion diagnostics in oncology drug development programs. More than 1,900 active oncology clinical trials worldwide integrate genomic sequencing data for targeted therapy selection and patient stratification. Cancer-related gene mutation testing continues to expand rapidly, with over 65% of advanced-stage cancer patients receiving genomic analysis before treatment selection. 

Proteomics: Proteomics is becoming a critical segment within the Cancer and Tumor Profiling Market due to increasing focus on protein biomarker identification and tumor progression analysis. Approximately 24% of cancer profiling procedures now incorporate proteomic technologies to evaluate protein expression, signaling pathways, and therapeutic response mechanisms. More than 58% of oncology researchers utilize proteomic platforms for biomarker discovery in breast, lung, and pancreatic cancers. Protein-based diagnostics gained substantial attention because nearly 45% of cancer-related biological activities are directly associated with protein regulation and abnormal cellular signaling. Mass spectrometry-based proteomics adoption increased by 34% across cancer research institutes due to improved sensitivity in detecting low-abundance biomarkers. More than 40% of pharmaceutical companies developing targeted oncology therapies rely on proteomic profiling during drug discovery and clinical validation phases. 

Metabolomics: Metabolomics is gaining strong momentum in the Cancer and Tumor Profiling Market due to increasing research on cancer metabolism and metabolic biomarker discovery. Approximately 16% of advanced oncology profiling studies now integrate metabolomic analysis for identifying tumor-associated metabolic changes and therapeutic response patterns. More than 47% of oncology researchers recognize metabolic reprogramming as a key factor in tumor growth and progression. Metabolomic testing adoption increased by 30% among cancer research centers focusing on early disease detection and precision oncology applications. Technological advancements in chromatography and mass spectrometry systems improved metabolite detection sensitivity by nearly 33%, enabling accurate characterization of tumor metabolism pathways. Around 41% of academic oncology institutions currently utilize metabolomics for cancer biomarker validation studies. 

Epigenetics: Epigenetics has emerged as an important segment in the Cancer and Tumor Profiling Market because of increasing research on DNA methylation, histone modification, and gene expression regulation in cancer progression. Approximately 12% of advanced cancer profiling procedures now involve epigenetic analysis for identifying abnormal gene regulation mechanisms associated with tumor development. More than 43% of oncology researchers focus on epigenetic biomarkers to improve early cancer detection and personalized therapy selection. DNA methylation testing adoption increased by 31% across molecular pathology laboratories due to rising demand for non-invasive cancer diagnostics. The integration of epigenetic profiling into oncology clinical trials expanded by 28%, particularly in studies involving colorectal, lung, and hematological cancers. More than 35% of pharmaceutical companies developing targeted oncology therapies utilize epigenetic biomarkers for patient stratification and treatment monitoring. 

BY APPLICATION

Personalized Cancer Medicine: Personalized cancer medicine represents the largest application segment in the Cancer and Tumor Profiling Market because of increasing adoption of targeted therapies and biomarker-driven treatment strategies. More than 55% of oncologists globally now utilize tumor profiling before initiating cancer treatment plans. Approximately 46% of advanced-stage cancer patients receive personalized therapy recommendations based on genomic or molecular profiling results. Precision oncology programs expanded by 42% across major cancer hospitals due to increasing demand for individualized treatment approaches. Biomarker-guided therapy selection improved treatment response rates by nearly 37% in patients with lung, breast, and colorectal cancers. More than 60% of pharmaceutical companies developing oncology drugs currently incorporate molecular profiling into clinical development programs. 

Oncological Diagnostics: Oncological diagnostics remains a critical application area within the Cancer and Tumor Profiling Market due to increasing demand for early cancer detection and accurate tumor characterization. Approximately 34% of total cancer profiling demand originates from oncology diagnostic laboratories performing genomic, proteomic, and biomarker-based testing procedures. More than 68% of oncology hospitals globally utilize molecular diagnostics for identifying actionable mutations and guiding treatment strategies. The use of next-generation sequencing in cancer diagnostics increased by 44% due to improved sensitivity and faster mutation detection capabilities. Liquid biopsy-based diagnostic testing expanded by 41%, supporting non-invasive cancer screening and recurrence monitoring applications. More than 52% of diagnostic laboratories now incorporate biomarker analysis into routine oncology testing workflows.

Research: Research applications represent a rapidly growing segment within the Cancer and Tumor Profiling Market due to increasing investments in oncology biomarker discovery, precision medicine, and multi-omics analysis. Approximately 20% of global cancer profiling activities are linked directly to academic research institutes, biotechnology laboratories, and pharmaceutical oncology development programs. More than 58% of cancer research organizations globally utilize genomic sequencing platforms for identifying novel therapeutic targets and understanding tumor heterogeneity. Multi-omics oncology research projects increased by 33% as institutions combine genomics, proteomics, metabolomics, and epigenetics to improve cancer characterization. More than 1,900 active oncology clinical studies currently involve tumor profiling technologies for biomarker validation and treatment response monitoring. 

Cancer and Tumor Profiling Market Regional Outlook

The Cancer and Tumor Profiling Market Regional Outlook demonstrates strong adoption of precision oncology technologies across North America, Europe, Asia-Pacific, and the Middle East & Africa. North America dominates with approximately 42% market share due to high genomic testing penetration, advanced oncology infrastructure, and increasing personalized medicine adoption. Europe accounts for nearly 29% share supported by biomarker research programs and government-funded cancer screening initiatives. Asia-Pacific contributes around 22% market share with rapid expansion of molecular diagnostics laboratories and increasing cancer prevalence across China, Japan, and India. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America remains the leading regional segment within the Cancer and Tumor Profiling Market, accounting for approximately 42% of total global market share due to extensive adoption of genomic diagnostics and personalized oncology treatment protocols. The region records more than 3.5 million molecular oncology testing procedures annually, with the United States contributing nearly 81% of regional testing activity. More than 72% of advanced cancer hospitals across North America utilize next-generation sequencing technologies for identifying actionable mutations and selecting targeted therapies. Liquid biopsy testing utilization increased by 41% due to the growing preference for minimally invasive cancer monitoring methods. Precision oncology adoption across North American healthcare systems expanded by 46%, supported by strong investments in biomarker discovery and companion diagnostic development. Approximately 58% of pharmaceutical oncology clinical trials conducted in the region incorporate genomic profiling for patient stratification and targeted drug validation. More than 65% of oncologists across the United States and Canada now recommend tumor profiling before initiating treatment protocols for lung, breast, colorectal, and prostate cancers. 

EUROPE

Europe represents approximately 29% of the global Cancer and Tumor Profiling Market Share due to expanding precision medicine initiatives, increasing cancer incidence, and strong government support for genomic healthcare programs. More than 2.8 million new cancer cases are diagnosed annually across Europe, increasing demand for advanced molecular diagnostics and biomarker profiling technologies. Approximately 64% of oncology hospitals within the region utilize genomic sequencing for identifying treatment-specific mutations and monitoring tumor progression. The adoption of liquid biopsy technologies increased by 34% across European oncology centers due to the growing demand for non-invasive cancer diagnostics and recurrence monitoring. Germany, France, and the United Kingdom account for nearly 61% of total oncology molecular testing procedures within Europe. More than 49% of European pharmaceutical oncology studies now integrate genomic and proteomic profiling into clinical research activities. 

GERMANY Cancer and Tumor Profiling Market

Germany accounts for approximately 27% of the European Cancer and Tumor Profiling Market Share due to its highly advanced healthcare infrastructure, strong biotechnology sector, and extensive adoption of precision oncology technologies. More than 520,000 new cancer cases are diagnosed annually in Germany, creating substantial demand for genomic profiling, biomarker testing, and targeted therapy selection. Approximately 69% of leading German oncology hospitals utilize next-generation sequencing technologies for identifying tumor-specific genetic mutations and monitoring treatment responses. Cancer biomarker screening programs in Germany increased by 36% due to rising awareness regarding early cancer detection and personalized treatment planning. Liquid biopsy adoption expanded by 33% across molecular diagnostic laboratories because of increasing demand for minimally invasive testing solutions. 

UNITED KINGDOM Cancer and Tumor Profiling Market

The United Kingdom contributes approximately 22% of the European Cancer and Tumor Profiling Market Share due to increasing investments in genomic medicine, oncology research, and national precision healthcare initiatives. More than 390,000 new cancer cases are diagnosed annually across the United Kingdom, increasing demand for molecular diagnostics and tumor profiling technologies. Approximately 63% of major oncology treatment centers in the country utilize genomic sequencing for targeted therapy selection and cancer mutation identification. The implementation of biomarker-based testing procedures increased by 37% across NHS-supported oncology laboratories. Liquid biopsy adoption expanded by 31% due to rising interest in non-invasive tumor monitoring and recurrence detection technologies. More than 51% of oncology-focused clinical trials in the United Kingdom currently integrate genomic profiling for patient stratification and therapeutic evaluation. 

ASIA-PACIFIC

Asia-Pacific accounts for approximately 22% of the global Cancer and Tumor Profiling Market Share and represents the fastest-expanding regional segment due to rising cancer prevalence, improving healthcare infrastructure, and increasing investments in genomic medicine. More than 9 million cancer cases are diagnosed annually across Asia-Pacific countries, creating strong demand for molecular diagnostics and precision oncology technologies. China, Japan, India, and South Korea collectively contribute nearly 74% of regional cancer profiling activities. The adoption of genomic sequencing technologies increased by 38% across oncology hospitals and research centers within Asia-Pacific. Liquid biopsy utilization expanded by 35% because of increasing awareness regarding non-invasive cancer diagnostics. More than 48% of oncology clinical studies in the region now incorporate biomarker-based profiling and targeted therapy evaluation. Government healthcare investments in cancer genomic screening programs increased by 33%, particularly in China and Japan. 

JAPAN Cancer and Tumor Profiling Market

Japan represents approximately 24% of the Asia-Pacific Cancer and Tumor Profiling Market Share due to advanced healthcare technologies, strong oncology research infrastructure, and increasing adoption of precision medicine. More than 1 million cancer cases are diagnosed annually in Japan, creating significant demand for molecular diagnostics and tumor profiling systems. Approximately 68% of major oncology hospitals in Japan utilize genomic sequencing technologies for identifying actionable mutations and guiding targeted therapy decisions. Biomarker-based testing utilization increased by 35% due to growing awareness regarding personalized treatment planning. Liquid biopsy procedures expanded by 32% across Japanese oncology laboratories because of increasing demand for minimally invasive cancer diagnostics. More than 49% of oncology clinical trials conducted in Japan currently integrate genomic profiling and biomarker analysis. Japan also records strong investments in multi-omics research initiatives involving genomics, proteomics, and epigenetics. 

CHINA Cancer and Tumor Profiling Market

China accounts for approximately 41% of the Asia-Pacific Cancer and Tumor Profiling Market Share due to rising cancer prevalence, expanding healthcare infrastructure, and increasing investments in genomic medicine. More than 4.8 million new cancer cases are diagnosed annually in China, significantly increasing demand for molecular diagnostics and tumor profiling technologies. Approximately 61% of advanced oncology hospitals across the country utilize genomic sequencing for cancer mutation detection and targeted therapy planning. The implementation of liquid biopsy technologies increased by 37% due to growing preference for non-invasive cancer diagnostics and treatment monitoring. More than 53% of oncology-focused research projects in China currently integrate biomarker profiling and genomic analysis. Precision oncology adoption expanded by 40% because of increasing awareness regarding personalized medicine and targeted treatment effectiveness. China also recorded a 36% increase in government-supported cancer screening programs involving molecular diagnostics technologies.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 7% of the global Cancer and Tumor Profiling Market Share due to improving healthcare infrastructure, increasing oncology awareness, and rising adoption of molecular diagnostic technologies. More than 1.5 million cancer cases are diagnosed annually across the region, generating growing demand for genomic profiling and precision oncology services. Countries including Saudi Arabia, the United Arab Emirates, South Africa, and Egypt collectively contribute nearly 68% of regional cancer profiling activities. The adoption of genomic sequencing technologies increased by 28% across oncology hospitals and diagnostic laboratories within the Middle East & Africa. Biomarker-based testing procedures expanded by 31% because of rising awareness regarding personalized cancer treatment approaches. Liquid biopsy utilization also increased by 26%, particularly among advanced oncology care centers seeking minimally invasive diagnostic solutions. 

List of Key Cancer and Tumor Profiling Market Companies

• Illumina, Inc.
• QIAGEN
• Genomic Health
• Neogenomics Inc.
• Life Sciences
• Oxford Gene Technology
• Bruker Spatial Biology, Inc.
• Ribomed Biotechnologies Inc.
• GenomeDX
• Guardant Health
• FOUNDATION MEDICINE, INC.

Top Two Companies with Highest Share

• Illumina, Inc.: Holds approximately 24% market participation in oncology sequencing technologies with over 65% adoption across advanced cancer genomics laboratories.
• QIAGEN: Accounts for nearly 18% share in oncology biomarker testing solutions with more than 52% utilization across companion diagnostic workflows.

Investment Analysis and Opportunities

The Cancer and Tumor Profiling Market continues to attract substantial investment activity due to rising precision oncology adoption and increasing cancer prevalence globally. Approximately 46% of biotechnology investors are prioritizing genomic diagnostics and biomarker discovery technologies within oncology healthcare segments. Investments in next-generation sequencing platforms increased by 39% because of growing demand for high-throughput cancer mutation analysis. More than 42% of pharmaceutical companies expanded oncology biomarker partnerships to accelerate companion diagnostic development and targeted therapy commercialization. Venture capital participation in AI-enabled molecular diagnostics increased by 33%, reflecting growing interest in automated genomic interpretation and predictive cancer analytics.

Investment opportunities remain particularly strong in liquid biopsy technologies, multi-omics platforms, and cloud-based genomic data systems. Liquid biopsy research investments expanded by 41% due to increasing adoption of minimally invasive tumor monitoring procedures. Approximately 37% of oncology hospitals globally upgraded molecular diagnostic infrastructure to support personalized treatment workflows. Asia-Pacific countries experienced a 34% increase in public healthcare investments focused on cancer genomic screening programs. Additionally, around 31% of healthcare technology companies introduced AI-driven oncology analytics platforms to improve clinical efficiency. The Cancer and Tumor Profiling Market Opportunities are further supported by rising immunotherapy development programs, increasing precision medicine collaborations, and expanding integration of advanced sequencing technologies across hospital laboratories and biotechnology ecosystems.

New Products Development

The Cancer and Tumor Profiling Market is experiencing rapid new product development activity focused on advanced sequencing systems, liquid biopsy platforms, and AI-powered genomic analytics solutions. Approximately 45% of oncology diagnostic companies introduced upgraded next-generation sequencing panels designed to improve mutation detection sensitivity and workflow efficiency. More than 38% of newly launched oncology diagnostic products now integrate multi-gene biomarker analysis for precision therapy selection. Liquid biopsy product launches increased by 34% due to growing clinical demand for non-invasive cancer monitoring technologies.

Artificial intelligence integration has become a major focus in new oncology profiling product development. Around 36% of biotechnology firms launched automated genomic interpretation platforms capable of reducing analysis time by nearly 30%. Multi-omics diagnostic systems combining genomics, proteomics, and metabolomics increased by 29% among newly commercialized oncology solutions. Additionally, approximately 32% of healthcare technology providers introduced cloud-based cancer data management platforms for secure genomic information sharing across hospitals and research centers. Growing demand for precision medicine, predictive oncology diagnostics, and personalized treatment planning continues driving innovation in advanced cancer profiling technologies worldwide.

Five Recent Developments

• Illumina, Inc.: Expanded its oncology sequencing portfolio by introducing enhanced multi-gene cancer panels capable of improving mutation detection sensitivity by nearly 35%, supporting faster molecular diagnostics across hospital laboratories and precision oncology programs globally.
• QIAGEN: Increased companion diagnostic capabilities through integration of advanced biomarker analysis technologies, improving targeted therapy identification efficiency by approximately 31% across oncology clinical testing workflows and pharmaceutical research collaborations.
• Guardant Health: Expanded liquid biopsy testing applications by enhancing circulating tumor DNA analysis systems, resulting in nearly 33% improvement in early-stage cancer detection accuracy for non-invasive oncology monitoring procedures.
• FOUNDATION MEDICINE, INC.: Introduced expanded genomic profiling solutions supporting over 40% higher biomarker coverage for precision oncology treatment planning and immunotherapy response evaluation across advanced cancer care programs.
• Bruker Spatial Biology, Inc.: Advanced spatial biology technologies through AI-enabled tissue profiling systems capable of improving tumor microenvironment analysis efficiency by approximately 28% within oncology research and biomarker discovery programs.

Report Coverage Of Cancer and Tumor Profiling Market

The Cancer and Tumor Profiling Market Report provides comprehensive analysis of global market trends, segmentation, regional outlook, competitive landscape, investment activity, and technological advancements influencing precision oncology development. The report evaluates key profiling technologies including genomics, proteomics, metabolomics, and epigenetics while assessing their adoption across personalized medicine, oncological diagnostics, and cancer research applications. Approximately 48% of the analysis focuses on genomic sequencing technologies because of their increasing utilization within targeted oncology treatment programs. The report also highlights that liquid biopsy procedures expanded by 41%, reflecting growing demand for minimally invasive cancer diagnostics and recurrence monitoring systems.

The report further examines regional market performance across North America, Europe, Asia-Pacific, and the Middle East & Africa using detailed market share analysis and oncology testing trends. More than 58% of leading oncology companies analyzed within the report focus on AI-driven molecular diagnostics and biomarker discovery initiatives. The Cancer and Tumor Profiling Market Research Report also evaluates precision medicine investments, multi-omics integration strategies, cloud-based genomic data management systems, and companion diagnostic development programs.